What Is Pramiracetam? A Research Compound Overview For Laboratory Use

Written By: Neat Digital, Research Content Writer

Reviewed By: Natalie Kunsman, M.D., Board-Certified Physician

Last Reviewed:  August 1, 2026

Disclaimer: Pramiracetam is sold by Nordic Chems strictly for research and educational purposes. It is not intended for human consumption, and it is not a food, cosmetic, or medical product. All materials referenced in this article are for qualified laboratory use only.

Pramiracetam increased high-affinity choline uptake (HACU) in rat hippocampal synaptosomes by 30% to 37% in a 1983 study published in Drug Development Research. That single finding, from Pugsley and colleagues at Parke-Davis, put this racetam-class chemical on the map for neuroscience investigators. And it remains one of the more specific data points in racetam research, because the HACU effect was isolated to the hippocampus. No change was observed in the cerebral cortex or corpus striatum.

Pramiracetam (CI-879) is a synthetic pyrrolidone-derived research chemical with the molecular formula C14H27N3O2 and a molecular weight of 262.4 g/mol. It belongs to the racetam family of materials, was first synthesized at Parke-Davis in the late 1970s, and has been the subject of peer-reviewed research into cholinergic mechanisms and spatial memory processes. It carries CAS number 68497-62-1 and is catalogued under PubChem CID 51712.

This article covers pramiracetam's chemical properties, published research findings, laboratory handling requirements, and what researchers should look for when sourcing this material. Everything here is framed for investigative and educational use.

What Is The Chemical Profile Of Pramiracetam?

Pramiracetam's IUPAC name is N-[2-[di(propan-2-yl)amino]ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide. That name tells you the structure: a 2-pyrrolidone ring (the defining feature of all racetam-class chemicals) connected via an acetamide bridge to a diisopropylaminoethyl side chain.

The diisopropylamine group is what separates pramiracetam from its parent material, piracetam. This structural modification makes pramiracetam lipophilic (fat-soluble), which has implications for how it crosses biological membranes in research models. Piracetam, by contrast, is water-soluble and lacks that diisopropylamine tail.

Here are the core specifications researchers need:

The sulfate salt form (CAS 72869-16-0) is also used in research. Researchers should confirm which form they're working with, as the molecular weight differs between the free base and the salt.

How Does Pramiracetam Interact With the Cholinergic System?

This is where pramiracetam gets interesting for laboratory investigators.

Pugsley, Shih, Coughenour, and Stewart published their analysis of pramiracetam's neurochemical properties in Drug Development Research in 1983. They administered pramiracetam sulfate at 100 mg/kg intraperitoneally (i.p.) to rats and measured changes across multiple neurotransmitter systems.

The negative findings are as informative as the positive one. Pramiracetam didn't alter concentrations of norepinephrine, dopamine, serotonin, 5-hydroxyindoleacetic acid, or homovanillic acid in any brain region tested. It showed zero affinity in vitro for dopaminergic, adrenergic, serotoninergic, GABAergic, muscarinic, adenosine, and benzodiazepine receptors. It didn't change d-methamphetamine-induced monoamine metabolism. And it had no effect on prolactin concentration in rat serum.

What it did do: pramiracetam caused a statistically significant increase in sodium-dependent high-affinity choline uptake (HACU) into hippocampal synaptosomes. This increase ranged from 30% to 37%. The effect was region-specific. The cerebral cortex and corpus striatum showed no change.

HACU is the rate-limiting step in acetylcholine synthesis. The high-affinity choline transporter (CHT) pulls choline into the presynaptic terminal, where choline acetyltransferase converts it to acetylcholine. By increasing HACU specifically in the hippocampus, pramiracetam appears to accelerate acetylcholine turnover in the brain region most associated with memory formation. The Pugsley team concluded that this cholinergic mechanism "could be at least partially responsible for the enhancement of cognition processes observed for this agent."

That's a careful conclusion, and it should be. This is a single animal study using one exposure level. But it established a specific, testable mechanism that no other racetam-class chemical had demonstrated with this degree of regional selectivity at the time.

What Did the Spatial Memory Research Find?

Three years after the Pugsley study, Murray and Fibiger published "The effect of pramiracetam (CI-879) on the acquisition of a radial arm maze task" in Psychopharmacology (1986, volume 89, pages 378 to 381).

Their design was straightforward. Rats received pramiracetam at two concentration levels (7.5 mg/kg and 15 mg/kg) daily before testing in a 16-arm radial maze. Nine arms were baited with food. This setup allowed the researchers to distinguish between two types of memory: reference memory (which arms are always baited, a long-term spatial map) and working memory (which arms have already been visited in a given session, a short-term record).

Both concentration levels produced a statistically significant improvement in reference memory performance over the 7-week testing period. The working memory component showed no significant change.

That split result matters. It suggests pramiracetam's activity in research models is selective, not a blanket effect on all memory processes. Reference memory relies on hippocampal function, which aligns with the HACU findings from Pugsley's group.

A separate one-trial recognition memory test (Sarter and Van der Linde, 1987) found that pramiracetam at a concentration of 30 mg/kg produced a significant improvement in retention when the intertrial interval was 24 hours. This adds a temporal dimension: the effect in that model appeared at longer intervals, not short ones.

A pilot study in healthy elderly subjects (mean age 64.8 years) also examined pramiracetam's effects alongside memory training. However, this was preliminary work and shouldn't be cited as proof of any specific outcome.

Disclaimer: The studies referenced above were conducted in controlled research settings. They do not constitute evidence of therapeutic benefit. Pramiracetam is not approved by the FDA for any medical use in the United States. All materials sold by Nordic Chems are for laboratory research only and are not for human consumption.

How Does Pramiracetam Compare to Other Racetam-Class Materials?

Researchers working with racetam-class chemicals frequently compare them because they share the 2-pyrrolidone core structure but differ in side-chain modifications and observed activity.

Pramiracetam's distinction in published literature is its specificity. Where piracetam's effects appear at higher concentrations and across broader receptor systems, pramiracetam's observed HACU activity was confined to one brain region at comparatively lower concentrations. Aniracetam, another fat-soluble racetam-class chemical available through Nordic Chems as a research-grade powder, acts on AMPA-type glutamate receptors, a different pathway entirely.

This isn't a ranking. Each material serves different research questions. The comparison helps investigators select the right chemical for their specific experimental model.

What Is Pramiracetam’s Regulatory Status?

Pramiracetam is not FDA-approved in the United States. The FDA has classified it as a "new substance" that is not generally recognized as safe and effective under Section 201(p) of the Federal Food, Drug, and Cosmetic Act. It has no approved medical use in the U.S.

In some international markets (parts of Europe, including Italy and several Eastern European countries), pramiracetam sulfate has been marketed under the brand name Pramistar for cognitive-related conditions. But those approvals are jurisdiction-specific and don't apply to the U.S. regulatory framework.

For U.S.-based researchers: pramiracetam is not a scheduled substance under the Controlled Substances Act. It can be legally obtained and used for research purposes. However, it cannot be marketed, sold, or represented as a dietary supplement, food additive, or therapeutic agent.

Nordic Chems sells pramiracetam exclusively for research and development use. All purchasers must confirm they'll use the material only for investigative purposes, handled by qualified and trained individuals, in compliance with applicable laws.

How Should Researchers Handle and Store Pramiracetam?

Proper storage directly affects experimental reproducibility. If the material degrades because of poor handling, your data is compromised before you run a single assay.

Nordic Chems specifies the following for its pramiracetam powder: store in a cool, dry location, tightly sealed, accessible only to qualified or authorized persons. The melting point (47 to 48°C) is relatively low, so temperature control matters more than it does for some other racetam-class materials. Room-temperature storage in a climate-controlled lab is generally sufficient, but avoid prolonged exposure to heat or direct sunlight.

Water solubility is 10 mg/mL. Researchers preparing solutions should note this when designing in vitro assays. For lipophilic administration routes in animal models, pramiracetam's fat-soluble nature allows dissolution in appropriate organic vehicles.

A Safety Data Sheet (SDS) is available for Nordic Chems' pramiracetam and should be reviewed before handling. Standard laboratory PPE (gloves, eye protection, lab coat) applies. The SDS is published on the product page.

Why Does Purity Verification Matter for Pramiracetam Research?

Here's a problem most blog articles on pramiracetam don't address: sourcing quality.

If your pramiracetam is 85% pure, your experiment isn't testing pramiracetam. It's testing pramiracetam plus 15% of whatever else is in the sample. Contaminants, unreacted precursors, degradation products, or filler can all affect results. A 2019 analysis in the journal Annals of Internal Medicine found that among tested dietary products in the U.S., roughly 12% contained unapproved substances or failed to meet label claims. That study looked at consumer products, not research chemicals, but the principle transfers: if you don't verify what you're working with, your data is suspect.

Nordic Chems addresses this by providing third-party Certificates of Analysis (COAs) for each batch of pramiracetam. These certificates are produced by independent laboratories and verify identity, purity, and concentration. The COA for pramiracetam is linked directly on the product page, alongside the Safety Data Sheet. All materials are manufactured in certified U.S. laboratories under documented quality control processes.

This isn't common in the space. Many suppliers provide no third-party testing data at all, or bury it behind a support ticket. If you're running a study that needs to withstand peer review, your chemical sourcing is part of your methods section.

What Are the Current Gaps in Pramiracetam Research?

The published literature on pramiracetam has a few notable limitations that researchers should consider.

Most mechanistic data comes from the Pugsley 1983 study. That's a single research group, using one concentration level (100 mg/kg), in one species (rat), published over 40 years ago. The HACU finding is specific and reproducible in the conditions described, but the field hasn't produced extensive follow-up work exploring different concentration ranges, species, or chronic vs. acute exposure models.

The Murray and Fibiger 1986 maze study is well-designed but also limited to rat models. The split between reference memory improvement and no working memory change is an interesting observation, but it needs replication across different experimental paradigms.

Human research is thin. The pilot study on elderly subjects is exactly that: a pilot with limited sample size and no control for the many variables that affect cognitive assessment in aging populations.

These aren't criticisms of the existing studies. They're honest descriptions of where the evidence stands. Pramiracetam remains a material of interest precisely because those initial findings were specific and mechanistically coherent. But the field is far from saturated.

Disclaimer: This article is provided for informational and educational purposes only. It does not constitute medical, legal, or professional advice. Pramiracetam is sold by Nordic Chems for research use only and is not for human consumption. The statements made in this article have not been evaluated by the U.S. Food and Drug Administration. This material is not intended to diagnose, treat, cure, or prevent any disease.

Frequently Asked Questions 

What is pramiracetam, and what is it used for in laboratory research?

Pramiracetam (CI-879, CAS 68497-62-1) is a synthetic racetam-class research chemical with the molecular formula C14H27N3O2. It was first synthesized at Parke-Davis in the late 1970s and has been studied in peer-reviewed research for its effects on high-affinity choline uptake (HACU) in hippocampal tissue. It is sold by Nordic Chems for investigative and educational purposes only, not for human consumption.

What is the mechanism of action observed in pramiracetam research?

In the Pugsley et al. 1983 study, pramiracetam increased sodium-dependent high-affinity choline uptake in rat hippocampal synaptosomes by 30% to 37%. This increase was region-specific (hippocampus only) and suggests the chemical may accelerate acetylcholine turnover in that brain area. It showed no affinity for dopaminergic, serotoninergic, GABAergic, muscarinic, adenosine, or benzodiazepine receptors.

Is pramiracetam FDA-approved in the United States?

No. The FDA does not recognize pramiracetam as safe and effective for any medical use. It is classified as a "new substance" under Section 201(p) of the Federal Food, Drug, and Cosmetic Act. Pramiracetam is not a controlled substance under the DEA's scheduling system, but it cannot be sold or marketed as a supplement, food additive, or therapeutic agent in the U.S.

How should pramiracetam be stored in a research laboratory?

Store pramiracetam in a cool, dry location in a tightly sealed container. Its melting point is 47 to 48°C, so avoid exposure to heat above room temperature. Access should be limited to qualified or authorized laboratory personnel. A Safety Data Sheet is available from Nordic Chems and should be reviewed before handling.

What concentration levels were used in published pramiracetam research?

The Pugsley 1983 study used 100 mg/kg administered intraperitoneally. Murray and Fibiger (1986) tested 7.5 mg/kg and 15 mg/kg daily in a radial arm maze protocol over 7 weeks. Sarter and Van der Linde (1987) used 30 mg/kg in a one-trial recognition memory test. All exposure levels were in rat models under controlled laboratory conditions.

How does pramiracetam differ from piracetam in chemical structure?

Both share a 2-pyrrolidone ring core. Pramiracetam adds a diisopropylaminoethyl side chain via an acetamide bridge, making it fat-soluble with a molecular weight of 262.4 g/mol. Piracetam (molecular weight 142.2 g/mol) is water-soluble and lacks this lipophilic modification. These structural differences affect membrane permeability and observed activity patterns in research models.

Where can researchers source verified pramiracetam for laboratory use?

Nordic Chems supplies pramiracetam as a research-grade powder manufactured in certified U.S. laboratories. Each batch includes a third-party Certificate of Analysis verifying identity, purity, and concentration. A Safety Data Sheet is also provided. All materials are sold for research and development use only.